GlassScriptPhysician profile
Adam Bosak
NPI 1710115423
$83,631.12
in general payments reported to CMS, 2019-2025
38 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $1,710 · 2021: $1,388 · 2022: $15K · 2023: $27K · 2024: $23K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Food and Beverage: $6,885 · Travel and Lodging: $895 · Education: $18.09 · Consulting Fee: $17.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,723.00 |
| Food and Beverage | $6,884.74 |
| Travel and Lodging | $895.33 |
| Education | $18.09 |
| Consulting Fee | $17.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $39,889.10 | 2019-2025 | Tyvaso, Remodulin, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $37,370.51 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,072.46 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Genzyme Corporation | $915.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $877.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $439.75 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $301.61 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $253.63 | 2024-2025 | Winrevair, Zerbaxa |
| Genentech USA, INC. | $242.88 | 2019-2025 | Xolair |
| Grifols USA, LLC | $239.98 | 2024-2025 | Xembify |
| Advanced Respiratory, INC | $216.53 | 2020-2021 | |
| Inspire Medical Systems, INC. | $181.67 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $174.03 | 2019-2021 | |
| Electromed, INC. | $166.81 | 2019-2024 | Smartvest |
| Csl Behring | $149.73 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $143.42 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $111.38 | 2019-2024 | (8874) Incourage |
| Medtronic, INC. | $99.94 | 2024 | Kyphon Express II Kyphopak Tray |
| Gilead Sciences, INC. | $92.01 | 2019-2024 | Epclusa |
| Insmed, INC. | $84.49 | 2019-2025 | Arikayce |
| Boston Scientific Corporation | $76.79 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $61.08 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $57.48 | 2022 | |
| Sunovion Pharmaceuticals INC. | $57.04 | 2020-2021 | |
| Circassia INC. | $41.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.00 | 2020-2022 | |
| Inogen, INC. | $38.89 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.47 | 2021 | |
| Pharming Healthcare, INC. | $29.62 | 2024 | Ruconest |
| Abbott Laboratories | $29.33 | 2019-2025 | Mitraclip |
| Zoll Respicardia, INC. | $23.52 | 2024 | Remede System |
| Springworks Therapeutics, INC. | $22.12 | 2025 | Gomekli |
| Sandoz INC. | $20.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.00 | 2022 | |
| Mylan Specialty L.P. | $18.72 | 2019 | |
| Adma Biomanufacturing LLC | $17.45 | 2024 | |
| Pulmonx Corporation | $13.65 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Janssen Pharmaceuticals, INC | $8.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bosak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.